CFRX
$5.36
Contrafect
$.02
.37%
CFRX
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.27)
Revenue:  $0.00 Mil
Friday
Nov 13
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CFRX reports earnings?
Beat
Meet
Miss

Where is CFRX's stock price going from here?
Up
Flat
Down
Stock chart of CFRX
Analysts
Summary of analysts' recommendations for CFRX
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
ContraFect Corporation is a biotechnology company. The Company is focused on protein and antibody therapeutic products for life-threatening infectious diseases. Its product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of mAbs for the treatment of life-threatening seasonal and pandemic varieties of influenza. ContraFect Corporation is headquartered in Yonkers, New York.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalZoetisBristol-Myers SquibbJohnson & JohnsonMerck & Co.PfizerUltragenyx Pharmaceutical